ISIS Pharmaceuticals, Inc. Stock Nasdaq
Stocks
US4643301090
Biotechnology & Medical Research
| Market Cap | 7.31B 6.49B 6.07B 5.53B 10.42B 704B 10.56B 73.48B 28.44B 359B 27.45B 26.86B 1,152B | P/E 2026 * |
-12.3x | P/E 2027 * | -22.6x |
|---|---|---|---|---|---|
| Enterprise Value | 7.21B 6.4B 5.99B 5.46B 10.27B 694B 10.41B 72.44B 28.04B 353B 27.07B 26.48B 1,135B | EV / Sales 2026 * |
7.84x | EV / Sales 2027 * | 5.41x |
| Free-Float |
99.05% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ISIS Pharmaceuticals, Inc.
| 1 day | +1.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 2012-06-30 |
Brett Monia
CEO | Chief Executive Officer | 64 | 2019-12-31 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 2000-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 2005-12-12 |
| Director/Board Member | 73 | 2002-04-30 | |
Brett Monia
BRD | Director/Board Member | 64 | 2019-03-24 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.33% | +2.73% | - | - | 7.31B | |
| +4.16% | +3.04% | +49.37% | +94.17% | 74.41B | |
| -1.38% | -1.82% | +24.07% | +77.69% | 59.26B | |
| +1.32% | -0.07% | +4.87% | +35.27% | 47.14B | |
| -3.02% | -5.20% | +27.94% | +32.51% | 42.91B | |
| +0.31% | +3.02% | +348.95% | +643.82% | 44.13B | |
| -1.96% | -0.33% | +7.04% | +99.46% | 40.79B | |
| +3.32% | +3.49% | +10.10% | +51.23% | 30.77B | |
| -2.68% | +2.92% | +29.63% | +22.72% | 29.31B | |
| -4.86% | -10.66% | -26.27% | +330.06% | 23.71B | |
| Average | -0.36% | -0.52% | +52.86% | +154.10% | 43.6B | |
| Weighted average by Cap. | +0.02% | -0.32% | +58.02% | +145.77% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 920M 817M 764M 696M 1.31B 88.53B 1.33B 9.24B 3.58B 45.09B 3.45B 3.38B 145B | 1.36B 1.21B 1.13B 1.03B 1.94B 131B 1.97B 13.71B 5.31B 66.92B 5.12B 5.01B 215B |
| Net income | -576M -512M -479M -436M -821M -55.48B -832M -5.79B -2.24B -28.26B -2.16B -2.12B -90.76B | -330M -293M -274M -250M -471M -31.79B -477M -3.32B -1.28B -16.19B -1.24B -1.21B -52B |
| Net Debt | -103M -91.48M -85.55M -77.95M -147M -9.92B -149M -1.03B -401M -5.05B -387M -378M -16.22B | 68.31M 60.67M 56.74M 51.7M 97.34M 6.58B 98.68M 686M 266M 3.35B 256M 251M 10.76B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
